GLP-1 & compounded medication availability in Washington (2026)

Washington is neither the easiest state in this family nor the hardest. Everything OrderlyMeds carries ships here, and an online visit is a settled way to get a prescription, but the state’s pharmacy commission has published pointed expectations for how compounded GLP-1s must be made, and it has already acted against one pharmacy that fell short. This page lays out those expectations with citations, then the full ten-line picture.

Conditional state

Availability facts last reviewed: November 16, 2026

Washington availability across all ten lines

Availability of all ten OrderlyMeds product lines in Washington, with typical delivery times and notes
Product lineAvailable in Washington?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Patient-specific prescriptions, base form. The commission’s cited conditions are below.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same patient-specific basis as the semaglutide row.
NAD+ Yes 8–10 business days Nothing Washington-specific surfaced for this line.
Sermorelin Yes 8–10 business days Ships; no Washington-specific caveat found in this research pass.
Glutathione No N/A Not an OrderlyMeds product anywhere today.
BPC-157 Yes 8–10 business days In our catalog as an injectable; its federal record is below.
TB-500 Yes 8–10 business days Injectable in our catalog; its own section follows.
KPV No N/A Never carried, since our peptide lines are injectables only.
Epitalon Yes 8–10 business days Catalog injectable; read its federal record first.
MOTS-c Yes 8–10 business days Catalog injectable; its federal history reads differently from its four siblings.

Two No rows here are catalog facts, not Washington facts. We show them anyway, because a missing row is how availability pages mislead. Washington facts reviewed November 16, 2026.

The five research-peptide lines, as they stand in Washington

OrderlyMeds carries four of these five: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable. It carries KPV nowhere. Our research pass found no Washington-specific published position on these peptide lines, so what governs them here is the shared federal record, stated per line below, identical to what every other state page in this family says about them.

BPC-157 in Washington

Ships to Washington addresses as a compounded injectable on a patient-specific prescription. Its federal record, in full:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Washington

Also in the Washington catalog as an injectable, on the same patient-specific basis. The facts that travel with it:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Washington

Not available from OrderlyMeds in Washington or anywhere else, because our peptide lines are injectables and KPV is not one of them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Washington

Carried for Washington as a compounded injectable. Its record:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Washington

Ships here as a compounded injectable. Note that its federal history is its own, and it does not read like the four sections above.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Washington’s pharmacy regulators say about compounded medications

Washington’s pharmacy commission has not told compounders to stop. It has told them precisely how it expects GLP-1 compounding to be done, and it has backed those words with a real disciplinary record. Five cited facts shape what reaches a Washington address.

In a statement approved August 22, 2024, Washington’s Pharmacy Quality Assurance Commission stated that no salt form of semaglutide may be used in a compounded drug product, and that the active ingredient must be pharmaceutical grade (not “research use only”), accompanied by a valid certificate of analysis, and sourced from an FDA-registered establishment licensed in Washington; failure to comply may result in disciplinary or enforcement action. Source: Pharmacy Quality Assurance Commission statement (via the Washington Medical Commission).

An April 4, 2025 reminder of that statement, circulated after the federal GLP-1 shortages resolved, reaffirms that compounding essentially-copies of commercially available FDA-approved products is not permitted outside the recognized exceptions — including patient-specific customization — and cites the state’s own disciplinary hooks. Source: Washington State Nursing Commission reminder.

Out-of-state pharmacies that ship, mail, or deliver prescription drugs to Washington patients must be licensed by the Department of Health as nonresident pharmacies under RCW 18.64.360. Source: RCW 18.64.360.

Washington’s Uniform Telehealth Act provides that a practitioner-patient relationship may be established through telehealth — though not through email, instant messaging, text, or fax — with telehealth care held to the same professional standards as comparable in-person care. Source: Chapter 18.134 RCW.

The commission enforces: in March 2025 it issued a limited stop-service order against a Kirkland pharmacy that compounded semaglutide and tirzepatide, citing sterile-compounding failures and inadequate supervision. Source: Washington State Department of Health newsroom.

What that adds up to for an OrderlyMeds order: our partner pharmacies dispense into Washington under patient-specific prescriptions, using base semaglutide rather than salt forms, from licensed facilities, which is exactly the lane the commission’s statement draws. Pricing does not change at the state line; the number on our pricing page is the Washington number at every dose.

Washington availability FAQs

Is compounded semaglutide available in Washington?

Yes. OrderlyMeds ships compounded semaglutide to Washington addresses under patient-specific prescriptions, from licensed pharmacies working to the ingredient-sourcing conditions the state’s pharmacy commission has published. New customers start at $74/month for the first two months.

Can I get a prescription through an online visit in Washington?

Yes. Washington’s telehealth framework recognizes a provider-patient relationship established through a real telehealth encounter, though not through email or text alone. The regulator section above carries the citation.

Can I get BPC-157 or other research peptides shipped to Washington?

BPC-157, TB-500, Epitalon and MOTS-c: yes, as compounded injectables under a patient-specific prescription. KPV: no, because we compound these lines as injectables only. Each section above states that peptide’s own federal record, which reads the same in Washington as in every other state.

Why does this page call Washington a conditional state?

Because the state’s pharmacy commission has published specific conditions for GLP-1 compounding, on ingredient form and sourcing, and has taken real disciplinary action on compounding failures. The cited details are in the regulator section above.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone